Malaria treatment study for babies weighing 2 to under 5 kg
Part of Infections clinical trials.
This study tests a malaria medicine called Coartem Baby dispersible tablets in babies and infants who weigh between 2 and 5 kg and have uncomplicated malaria. The goal is to check how safe the medicine is and how well it works in this young age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be a boy or girl in the newborn or infant stage.
- Your baby's weight must be between 2 kg (about 4.4 pounds) and under 5 kg (about 11 pounds).
- Your baby must have a confirmed malaria infection (specifically Plasmodium falciparum or mixed infections including it), diagnosed by a quick test or microscope.
- Your baby should not have any allergy to artemether or lumefantrine (the active ingredients in the study medicine).
- Your baby must not have severe malaria or any heart rhythm problems (like long QT syndrome) or take medicines that affect heart rhythm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how artesunate works in infants under 2 years old being treated for severe malaria. It aims to learn more about the medicine to help improve treatment for babies.
This study follows people who were pregnant while receiving IV artesunate to better understand the treatment’s safety for both the mother and the baby. It does not test a new treatment—it collects safety information from real-world care.
This study tests a new malaria treatment for children with mild (uncomplicated) malaria. The goal is to see if the treatment safely and effectively clears the infection.
This trial tests how safe antimalarial drugs are during the first few months of pregnancy. It aims to find treatments that protect both mother and baby.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.